CLASS ACTION UPDATE for CODX, KSS and FLGT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / October 5, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
CODX Shareholders Click Here: https://www.zlk.com/pslra-1/co-dx-lawsuit-loss-submission-form?prid=32428&wire=1
KSS Shareholders Click Here: https://www.zlk.com/pslra-1/kohls-class-action-loss-submission-form?prid=32428&wire=1
FLGT Shareholders Click Here: https://www.zlk.com/pslra-1/fulgent-genetics-lawsuit-loss-submission-form?prid=32428&wire=1
* ADDITIONAL INFORMATION BELOW *
Co-Diagnostics, Inc. (NASDAQ:CODX)
This lawsuit is on behalf of a class of all persons and entities who purchased the publicly traded securities of Co-Dx during the period of May 12, 2022 through the close of the market on August 11, 2022 (4:00 p.m. ET).
Lead Plaintiff Deadline : October 17, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/co-dx-lawsuit-loss-submission-form?prid=32428&wire=1
According to the filed complaint, (i) demand for the Company’s Logix Smart™ COVID-19 test had plummeted throughout the quarter ended June 30, 2022, and (ii) as a result, defendants’ positive statements about the demand for its Logix Smart™ COVID-19 test lacked a reasonable basis.
Kohl’s Corporation (NYSE:KSS)
KSS Lawsuit on behalf of: investors who purchased October 20, 2020 – May 19, 2022
Lead Plaintiff Deadline : November 1, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/kohls-class-action-loss-submission-form?prid=32428&wire=1
According to the filed complaint, during the class period, Kohl’s Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Kohl’s new strategic framework to “drive top-line growth,” “expand operating margin,” and become “the most trusted retailer of choice for the active and casual lifestyle” (the “Strategic Plan”) was not well tailored to achieving the Company’s stated goals; (ii) the defendants had likewise overstated the Company’s success in executing its Strategic Plan; (iii) Kohl’s had deficient disclosure controls and procedures, internal control over financial reporting, and corporate governance mechanisms; (iv) as a result, the Company’s board of directors was able to and did withhold material information from shareholders about the state of Kohl’s in the lead-up to the Company’s annual meeting; (v) all the foregoing, once revealed, was likely to have a material negative impact on Kohl’s financial condition and reputation; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Fulgent Genetics, Inc. (NASDAQ:FLGT)
FLGT Lawsuit on behalf of: investors who purchased March 22, 2019 – August 4, 2022
Lead Plaintiff Deadline : November 21, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fulgent-genetics-lawsuit-loss-submission-form?prid=32428&wire=1
According to the filed complaint, during the class period, Fulgent Genetics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent’s revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; (iv) the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/719269/CLASS-ACTION-UPDATE-for-CODX-KSS-and-FLGT-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
Published Wed, 05 Oct 2022 21:06:04 -0500
Comments are closed.